Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors


Manage episode 347804499 series 1058605
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.

441 episodes